A New Oral Option for Management of Endometriosis-Associated Pain
Danielle Kroft2020-10-06T02:16:59-05:00FDA approval of gonadotropin-releasing hormone (GnRH) antagonist elagolix as an oral agent for management of moderate-to-severe pain associated with endometriosis provides an important treatment option for a condition that compromises quality of life for approximately 10% of women of reproductive age. Types of pain associated with endometriosis include painful periods, painful ovulation, pain during or [...]